Clinical Trials Update: March 20, 2007

(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:

Anemic Cancer

This study will evaluate the effectiveness of Procrit versus Aranesp in different doses given every three weeks in people with anemic cancer. Volunteers receiving at least 12 weeks of chemotherapy who do not have anemia due to any cause other than chemotherapy may qualify.

The research site is in Gainesville, Fla.

More information

Please see http://www.centerwatch.com/patient/studies/cat458.html.

WHAT TO KNOW
    • Anemic Cancer
    • Breast Cancer
    • Fibrocystic Breast Disease

-----

Breast Cancer

This study will evaluate the effectiveness of a combination of hormonal agents (anastrozole and fulvestrant), versus anastrozole alone on women with breast cancer. Postmenopausal women with pathologically confirmed metastatic breast cancer may be eligible. Patients with known brain or CNS metastases are not eligible, and additional criteria apply.

The research site is in Elgin, Ill.

More information

Please see http://www.centerwatch.com/patient/studies/cat29.html.

-----

Fibrocystic Breast Disease

This study will evaluate cyclic breast pain associated with the menstrual cycle in women diagnosed with fibrocystic breast disease. Women 18-50 with normal thyroid function and no history of thyroid disease who have at least six days per cycle of moderate-to-severe clinical pain may be included. Patients cannot have begun or changed hormonal therapy within six months of enrollment, including birth control pills, hormone replacement therapy, and any progestin including Norplant or Depo-Provera.

The research site is in Lexington, Ky.

More information

Please see http://www.centerwatch.com/patient/studies/cat392.html.

-----

Copyright 2007 Thomson CenterWatch. All rights reserved.

Join the Discussion
You are using an outdated version of Internet Explorer. Please click here to upgrade your browser in order to comment.
blog comments powered by Disqus
 
You Might Also Like...